Optometrists in San Fernando, CA Accepting Medicare
8 Optometrists found. Showing 1 - 8
 Anais Chorbadjian Od, A Professional Corp Optometrist Medicare: Medicare Enrolled Practice Location: 602 N Maclay Ave Unit A, San Fernando, CA 91340 Phone: 818-606-3554 |
 Dr. Marianna Tovmasyan Petrosyan, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1011 Glenoaks Blvd., San Fernando, CA 91340 Phone: 818-925-2225 Fax: 818-925-2212 |
Affordable Vision Center Inc Optometrist Medicare: Medicare Enrolled Practice Location: 906 San Fernando Rd, San Fernando, CA 91340 Phone: 818-361-1513 Fax: 818-361-5443 |
Mitra Foroodi Optometrist Medicare: Not Enrolled in Medicare Practice Location: 906 San Fernando Rd, San Fernando, CA 91340 Phone: 818-294-9392 |
Clear Vision Optometry, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1101 Truman St, Suite E, San Fernando, CA 91340 Phone: 818-361-2020 |
Marianna Petrosyan O.d. An Optometric Corporation Optometrist Medicare: Medicare Enrolled Practice Location: 1009 Glenoaks Blvd, San Fernando, CA 91340 Phone: 818-281-6148 |
Complete Eye Care Center Optometry Optometrist Medicare: Medicare Enrolled Practice Location: 1101 Truman St, Suite E, San Fernando, CA 91340 Phone: 818-361-2020 Fax: 818-361-6381 |
Dr. Leyen Lim, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 1101 Truman St, Suite E, San Fernando, CA 91340 Phone: 818-361-2020 Fax: 818-361-6381 |
News Archive
VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
New drug therapies that target glutamate pathway may be effective for subgroups of patient with schizophrenia
Mounting evidence indicates that disturbances in the brain's glutamate pathway contribute to symptoms of schizophrenia. Thus, the glutamate pathway has become the target of a number of new drug therapies. Findings published in the journal Biological Psychiatry suggest that at least one of these drugs may be an effective treatment for individuals in the early course of the illness.
Researchers identify mechanisms that regulate mammary gland development
Publication in Nature Cell Biology: researchers at the Université libre de Bruxelles, ULB define for the first time the mechanisms responsible for the mammary gland development.
Response Biomedical first quarter total revenues increase 59% to $2,470,560
Response Biomedical Corporation reported financial results for the first quarter ended March 31, 2011. Total revenues for the three-month period ended March 31, 2011 increased 59% to $2,470,560 compared to $1,549,479 for the same period last year.
› Verified 1 days ago
Chiropractors
Optometrists
Physical Therapists
Podiatrists
Speech-Language Pathologists